Kymera Therapeutics, Inc.
KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$115.43
Price-0.89%
-$1.04
1Y
Price
Market Cap
$9.495b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-94.0%
EBITDA Margin-94.2%
Net Profit Margin-83.9%
Free Cash Flow Margin-94.0%
EBITDA Margin-94.2%
Net Profit Margin-83.9%
Free Cash Flow MarginRevenue
$104.989m
+167.8%
1y CAGR+37.0%
3y CAGR+44.7%
5y CAGREarnings
-$299.650m
+3.8%
1y CAGR-29.2%
3y CAGR-20.6%
5y CAGREPS
-$3.25
+11.9%
1y CAGR-10.0%
3y CAGR-4.5%
5y CAGRBook Value
$1.509b
$1.645b
Assets$139.852m
Liabilities$82.222m
DebtDebt to Assets
5.0%
-0.3x
Debt to EBITDAFree Cash Flow
-$237.956m
-1.5%
1y CAGR-21.9%
3y CAGR-13.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company